Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chimerix Inc (NQ: CMRX )

0.9726 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.9726
Bid (Size) 0.9300 (1)
Ask (Size) 1.040 (5)
Prev. Close 0.9726
Today's Range 0.9726 - 0.9726
52wk Range 0.8800 - 2.395
Shares Outstanding 86,249,744
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development 
From Chimerix, Inc.
Via GlobeNewswire

Performance

YTD
-47.99%
-47.99%
1 Month
+3.26%
+3.26%
3 Month
-14.68%
-14.68%
6 Month
-32.92%
-32.92%
1 Year
-55.18%
-55.18%

More News

Read More
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Earnings Outlook For Chimerix
Via Benzinga
4 Analysts Have This to Say About Chimerix
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Chimerix Earnings Preview
Via Benzinga
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
From Chimerix, Inc.
Via GlobeNewswire
NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Chimerix to Participate in Upcoming Investor Conferences
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
From Chimerix, Inc.
Via GlobeNewswire
CMRX Stock Warning! Smart Biotech Investors Will Avoid Chimerix Like the Plague.
Via InvestorPlace
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes
Via InvestorPlace
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
From Chimerix, Inc.
Via GlobeNewswire
7 Small-Cap Stocks to Buy Before the Breakout
Via InvestorPlace
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
Via InvestorPlace
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
From Chimerix, Inc.
Via GlobeNewswire
7 Deeply Undervalued Growth Stocks to Buy in June
Via InvestorPlace
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House
From Chimerix, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023
Via Benzinga
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
From Chimerix, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.